{"id":88557,"date":"2024-12-25T23:35:06","date_gmt":"2024-12-25T23:35:06","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/aplt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-applied-therapeutics-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/"},"modified":"2024-12-25T23:35:06","modified_gmt":"2024-12-25T23:35:06","slug":"aplt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-applied-therapeutics-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/aplt-investor-alert-bronstein-gewirtz-grossman-llc-announces-that-applied-therapeutics-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit\/","title":{"rendered":"APLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit"},"content":{"rendered":"
\n

NEW YORK, Dec. 25, 2024 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Applied Therapeutics, Inc. (\u201cApplied Therapeutics\u201d or \u201cthe Company\u201d) (NASDAQ: APLT) and certain of its officers.<\/p>\n

Class Definition<\/strong><\/p>\n

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024 and December 2, 2024, both dates inclusive (the \u201cClass Period\u201d). Such investors are encouraged to join this case by visiting the firm\u2019s site: bgandg.com\/APLT<\/u><\/a>.<\/p>\n

Case Details<\/strong><\/p>\n

The Complaint alleges that throughout the Class Period, Defendants made false and\/or misleading statements and\/or failed to disclose that: (1) the New Drug Application (NDA) for govorestat contained deficiencies that would preclude FDA approval; (2) the clinical data submitted in support of the NDA was insufficient to demonstrate efficacy or safety; (3) as a result of the foregoing, the Company\u2019s prior positive statements regarding the likelihood of govorestat\u2019s approval were materially false and misleading; and (4) as a result, Applied Therapeutics\u2019 public statements were materially false, misleading, or lacked a reasonable basis when made.<\/p>\n

What’s Next?<\/strong><\/p>\n

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm\u2019s site: bgandg.com\/APLT<\/u><\/a>. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660<\/u>. If you suffered a loss in Applied Therapeutics you have until February 18, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.<\/p>\n

There is No Cost to You<\/strong><\/p>\n

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys\u2019 fees, usually a percentage of the total recovery, only if we are successful.<\/p>\n

Why Bronstein, Gewirtz & Grossman<\/strong><\/p>\n

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.<\/p>\n

Follow us for updates on LinkedIn<\/u><\/a>, X<\/u><\/a>, Facebook<\/u><\/a>, or Instagram<\/u><\/a>.<\/p>\n

Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n

Contact<\/strong><\/p>\n

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660<\/u> | info@bgandg.com<\/u><\/a><\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Dec. 25, 2024 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Applied Therapeutics, Inc. (\u201cApplied Therapeutics\u201d or \u201cthe Company\u201d) (NASDAQ: APLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages […]<\/p>\n","protected":false},"author":2,"featured_media":88558,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/a0da9a10-1592-437a-9c10-d30eeb243cb7","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-88557","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t